Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-Versus-Host Disease

Autologous/syngeneic stem cell transplantation to treat refractory GvHD

Summary:

Severe graft-versus-host disease (GvHD) refractory to corticosteroids responds poorly to experimental treatment and is often fatal. Attempts have been made to ‘rescue’ such patients by transfusing autologous cells in order to ablate the lymphoid component of the graft or to introduce regulatory cells capable of suppressing the GvHD. Here, we report details of eight patients with severe grade III–IV acute GvHD (n=7) or extensive chronic GvHD (n=1) who after failing a median of four lines of treatment were then treated with either autologous or syngeneic nucleated cell transfusions. Patients received standard conditioning (n=3), low intensity (n=2) or no conditioning (n=3) before the rescue procedure. In four of the five patients who received some form of conditioning, mixed chimerism or complete recipient hematopoiesis was restored. The GvHD resolved in four patients, of whom one died subsequently of multiorgan failure and two died of leukemia; one is still alive. A fifth patient had transient improvement in GvHD, which recurred when the corticosteroids were reduced. Three patients obtained no benefit from the procedure. We conclude that ‘rescue’ by transfusion of autologous or syngeneic nucleated cells may be valuable to treat severe refractory GvHD; the best approach to conditioning remains to be defined.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Gratwohl A, Brand R, Apperley J et al. Graft-versus host disease and outcome in HLA-identical sibling transplantation for chronic myeloid leukemia. Blood 2002; 100: 3877–3886.

    Article  CAS  Google Scholar 

  2. Ferrara J, Teshima T . Understanding the alloresponse: new approaches to graft-versus-host disease prevention. Semin Hematol 2002; 39: 15–22.

    Article  Google Scholar 

  3. Mehta J, Powles R, Singhal S et al. Outcome of autologous rescue after failed engraftment of allogeneic marrow. Bone Marrow Transplant 1996; 17: 213–217.

    CAS  Google Scholar 

  4. McSweeney P, Niederwieser D, Shizuru J et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390–3400.

    Article  CAS  Google Scholar 

  5. Taylor PA, Friedman TM, Korngold R et al. Tolerance induction of alloreactive T cells via ex vivo blockade of the CD40:CD40L costimulatory pathway results in the generation of a potent immune regulatory cell. Blood 2002; 99: 4601–4609.

    Article  CAS  Google Scholar 

  6. Bordignon C, Thomis D, Marktel S et al. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 2001; 97: 1249–1257.

    Article  Google Scholar 

  7. Taylor PA, Lees CJ, Blazar BR . The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002; 99: 3493–3499.

    Article  CAS  Google Scholar 

  8. Edinger M, Hoffmann P, Ermann J et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003; 9: 1144–1150.

    Article  CAS  Google Scholar 

  9. Martin PJ, Schoch G, Fisher L et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 1991; 77: 1821–1828.

    CAS  Google Scholar 

  10. Weiss L, Slavin S . Prevention and treatment of graft-versus-host disease by down-regulation of anti-host reactivity with veto cells of host origin. Bone Marrow Transplant 1999; 23: 1139–1143.

    Article  CAS  Google Scholar 

  11. Pusic I, Pavletic SZ, Kessinger A et al. Pseudoautologous blood stem cell transplantation for refractory chronic graft-versus-host disease. Bone Marrow Transplant 2002; 29: 709–710.

    Article  CAS  Google Scholar 

  12. Nagashima T, Sato F, Chuma T et al. Chronic demyelinating polyneuropathy in graft-versus-host disease following allogeneic bone marrow transplantation. Neuropathology 2002; 22: 1–8.

    PubMed  Google Scholar 

  13. Westermann J, Bode U . Distribution of activated T cells migrating through the body: a matter of life and death. Immunol Today 1999; 20: 302–306.

    Article  CAS  Google Scholar 

  14. Wiesmann A, Bader P, Bamberg M et al. Severe acute graft-versus-host disease after T-cell depleted allogeneic stem cell graft from a second donor caused by persisting T-cells from the 1st donor. Bone Marrow Transplant 2003; 32: 511–513.

    Article  CAS  Google Scholar 

  15. Taranova AG, Georges GE, Yunusov M et al. Breaking tolerance in stable mixed chimeric dogs with low-dose TBI and donor or recipient lymphocyte infusion. Blood 2003; 102: 76a (Abstr. 256).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J R Passweg.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Passweg, J., Orchard, K., Buergi, A. et al. Autologous/syngeneic stem cell transplantation to treat refractory GvHD. Bone Marrow Transplant 34, 995–998 (2004). https://doi.org/10.1038/sj.bmt.1704658

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704658

Keywords

This article is cited by

Search

Quick links